Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
31.82
+0.77 (2.48%)
Dec 20, 2024, 4:00 PM EST - Market closed
Avidity Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 10.12 | 9.56 | 9.22 | 9.33 | 6.79 | 2.32 | |
| Revenue Growth (YoY) | -0.19% | 3.64% | -1.09% | 37.41% | 192.67% | 511.87% | |
| Cost of Revenue | 260.79 | 190.97 | 150.4 | 101.18 | 37.6 | 14.54 | |
| Gross Profit | -250.67 | -181.41 | -141.18 | -91.86 | -30.82 | -12.22 | |
| Selling, General & Admin | 74.02 | 54.19 | 37.73 | 26.2 | 13.46 | 5.11 | |
| Operating Expenses | 74.02 | 54.19 | 37.73 | 26.2 | 13.46 | 5.11 | |
| Operating Income | -324.69 | -235.6 | -178.91 | -118.05 | -44.28 | -17.33 | |
| Interest Expense | - | - | - | - | -0.21 | -7.39 | |
| Interest & Investment Income | 44.76 | 23.97 | 4.98 | 0.1 | 0.21 | - | |
| Other Non Operating Income (Expenses) | -0.55 | -0.59 | -0.06 | -0.06 | -0.08 | -0.02 | |
| Pretax Income | -280.49 | -212.22 | -174 | -118.01 | -44.36 | -24.73 | |
| Net Income | -280.49 | -212.22 | -174 | -118.01 | -44.36 | -24.73 | |
| Net Income to Common | -280.49 | -212.22 | -174 | -118.01 | -44.36 | -24.73 | |
| Shares Outstanding (Basic) | 98 | 73 | 52 | 41 | 22 | 3 | |
| Shares Outstanding (Diluted) | 98 | 73 | 52 | 41 | 22 | 3 | |
| Shares Change (YoY) | 44.08% | 39.97% | 25.91% | 91.24% | 698.49% | 9.53% | |
| EPS (Basic) | -2.85 | -2.91 | -3.34 | -2.85 | -2.05 | -9.12 | |
| EPS (Diluted) | -2.85 | -2.91 | -3.34 | -2.85 | -2.05 | -9.12 | |
| Free Cash Flow | -188.51 | -123.29 | -139.09 | -98.55 | -38.21 | 2.26 | |
| Free Cash Flow Per Share | -1.91 | -1.69 | -2.67 | -2.38 | -1.76 | 0.83 | |
| Operating Margin | -3209.34% | -2464.41% | -1939.65% | -1265.83% | -652.38% | -747.39% | |
| Profit Margin | -2772.44% | -2219.87% | -1886.33% | -1265.38% | -653.53% | -1066.58% | |
| Free Cash Flow Margin | -1863.31% | -1289.67% | -1507.92% | -1056.76% | -562.97% | 97.24% | |
| EBITDA | -322.04 | -233.5 | -177.53 | -117.41 | -43.9 | -16.98 | |
| D&A For EBITDA | 2.65 | 2.1 | 1.39 | 0.64 | 0.37 | 0.35 | |
| EBIT | -324.69 | -235.6 | -178.91 | -118.05 | -44.28 | -17.33 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.